JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yahav, J.
Right arrow Articles by Jonas, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yahav, J.
Right arrow Articles by Jonas, A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 2000, p. 3534-3537, Vol. 38, No. 10
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Relevance of CagA Positivity to Clinical Course of Helicobacter pylori Infection in Children

J. Yahav,1 A. Fradkin,2 B. Weisselberg,2 A. Diver-Haver,2 H. Shmuely,1 and A. Jonas2

Helicobacter Research Center, Rabin Medical Center, Beilinson Campus, Petah Tiqva,1 and Pediatric Gastroenterology Unit, Chaim Sheba Medical Center, Tel Hashomer,2 Israel

Received 23 February 2000/Returned for modification 28 June 2000/Accepted 25 July 2000

A potential virulence determinant of Helicobacter pylori is the cagA gene product. To determine the relevance of the expression of CagA to the clinical picture and outcome of H. pylori infection in children, we examined 104 consecutive children diagnosed with H. pylori infection. Serum samples were collected to test for the presence of immunoglobulin G (IgG) anti-CagA antibodies. Forty-five patients (43%) had antibodies to the CagA protein (group I), and 59 did not (group II). Seropositive patients had a longer prediagnostic history of abdominal pain (P = 0.02), more severe abdominal pain (defined as ulcer pain) (P = 0.05), a higher prevalence of duodenal ulcer (38 versus 7%; P < 0.01), more active chronic gastritis (82 versus 32%; P < 0.001), and a higher titer of serum IgG anti-H. pylori antibodies (P < 0.001). Ninety percent of the patients were monitored for 27 ± 18 months. On multivariate analysis, CagA-negative patients had a 3.8-fold-higher chance of achieving a disease-free state than CagA-positive patients (95% confidence interval, 1.5- to 9.5-fold). We conclude that infection with CagA-producing strains of H. pylori is a risk factor for severe clinical disease and ongoing infection.


Journal of Clinical Microbiology, October 2000, p. 3534-3537, Vol. 38, No. 10
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.